An Open-label Clinical Study of Chronic L-theanine Supplementation in Patients with Major Depressive Disorder (P12-007-19)

everhopeful · June 22, 2019, 10:03am

ncbi.nlm.nih.gov

An Open-label Clinical Study of Chronic L-theanine Supplementation in Patients with Major Depressive Disorder (P12-007-19).

S Hidese, M Ota, H Ozawa, T Okubo and H Kunugi, Current developments in nutrition, Jun 2019

The present study is designed to investigate the effectiveness of L-theanine (Suntheanine®) among patients with major depression disorder (MDD).Twenty patients were recruited with moderate MDD (4 males; mean age: 41.0 ± 14.1 years, and 16 females; 42.9 ± 12.0 years) for this open-label clinical study. Participants were supplemented with L-theanine (250 mg/day) along with their current medication for 8 consecutive weeks. The cognitive functions and related symptoms were evaluated at baseline, 4 weeks, and 8 weeks after L-theanine supplementation using advanced version (21-items) of the Hamilton Depression Rating Scale (HAMD-21), Pittsburgh Sleep Quality Index (PSQI), State-Trait Anxiety Inventory (STAI), Brief Assessment of Cognition in Schizophrenia (BACS), including the Stroop test.L-theanine supplementation effectively lowered the HAMD-21 score (P = 0.007), and reduction was also observed in unremitted patients (HAMD-21 > 7; P = 0.004) at baseline. STAI test results indicated a significant decrease in Anxiety-trait scores (P = 0.012) after L-theanine supplementation. PSQI scores also decreased in the unremitted patients at baseline after L-theanine intake (P = 0.030). Concerning to the cognitive functions, response latency (P = 0.001) and error rate (P = 0.036) were lowered in the Stroop test, while executive function (P = 0.016) and verbal memory (P = 0.005) were significantly enhanced in the BACS test after L-theanine supplementation.This study demonstrates that chronic L-theanine supplementation (8 weeks) is quite safe and features with diverse beneficial effects on the improvement of depressive symptoms, sleep disturbance, anxiety, and cognitive impairment functions in patients with MDD.This study was supported by an unrestricted research grant provided by the Taiyo Kagaku Co. Ltd.

system · September 20, 2019, 10:03am

This topic was automatically closed 90 days after the last reply. New replies are no longer allowed.

Topic		Replies	Views
Effects of Chronic L-theanine on Stress-related Symptoms and Cognitive Function in a Non-clinical Population: A Randomized Controlled Trial (P06-106-19) News	0	245	June 22, 2019
Psychotropic effects of L-theanine and its clinical properties: from the management of anxiety and stress to a potential use in schizophrenia News	2	290	August 16, 2019
L-theanine is Effective in Lessening Positive Symptoms, and improving Sleep Quality in patients with schizophrenia News	437	93144	May 14, 2025
My experiment with Beta-Alanine for a week Medications	0	958	April 29, 2018
Lower antipsychotic dosage with L-theanine? DX'd - Other	10	275	September 21, 2020

An Open-label Clinical Study of Chronic L-theanine Supplementation in Patients with Major Depressive Disorder (P12-007-19)

Related topics